Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
YM BioSciences
Age
3–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Patients with recurrent, diffuse intrinsic pontine gliomas
Patients should have had 2 of the following 3 neurological symptoms: cranial nerve deficit, long tract signs, ataxia and a onset prior to initial diagnosis \< 6 months.
Evidence of disease progression
Have a Lansky or Karnofsky Performance Status of \> 40
Be between the age \>3 years to \< 18 years of age
Have a tumor that is measurable radiologically
For female patients of childbearing age: presence of a negative pregnancy test within 7 days prior to day 0.
Use of effective contraception
Adequate hematological, renal, and hepatic function
You may not be if
A history of prior use of EGFR-targeting agents (monoclonal antibodies, tyrosine kinase inhibitors)
More than one line of treatment
Had radiation therapy completed within 12 weeks of enrollment
Previous chemotherapy completed \< 2 weeks prior to enrollment
If female, is pregnant or lactating
Has other existing serious medical conditions
Has any condition, therapy, or medical condition, which, in the opinion of the attending physician could represent a risk for the patient or adversely affect the study objectives
Is currently taking or planning to take other investigational drugs during the study
Known contraindications against antibodies
Clareo Health | Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
